Novo Nordisk's Cagri-Sema Evergreening The Franchise Part I Novo Nordisk, the leader in weight loss market, is going after tolerability instead of efficacy with this combination drug targeting GLP-1 and amylin
However, even in people without diabetes, optimising natural GLP-1 production may support metabolic health, potentially reduce appetite, and possibly contribute to maintaining insulin sensitivity
Studies have demonstrated that Semaglutide can reduce the risk of major cardiovascular events, such as heart attack and stroke, in individuals with type 2 diabetes
We still need to remember that: Lipedema fat is not normal fat. It does not respond to calorie restriction the way typical fat does
During this time, some patients may see a slight reduction in appetite, while weight loss is often modest
Whats happening: The digital health platform launched a free tier of its microhabits app and named actress Rebel Wilson as a wellness ambassador